Skip to main content
Premium Trial:

Request an Annual Quote

Eli Lilly Transfers Bioanalytical Drug Discovery Capabilities to Advion

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Advion BioServices today said that under a new, multi-year contract it will provide drug giant Eli Lilly with drug discovery bioanalytical services

In addition, it said that Lilly will transition its drug discovery bioanalytical capability to Advion BioServices, which is a subsidiary of Advion BioSciences. All Lilly employees impacted by the transfer will have the opportunity to join Advion.

Financial terms of the transaction were not disclosed.

The new contract is part of Advion's plans to open a 22,000 square-foot drug discovery bioanalytical laboratory in the Purdue Research Park of Indianapolis' technology center at the Ameriplex Business Park near the Indianapolis International Airport. Ithaca, NY-based Advion expects the lab to be fully operational by the end of May 2011.

"The establishment of this laboratory in Indianapolis further strengthens our relationship with Lilly as a key partner in bioanalytical services while positioning Advion to be one of the largest and most-respected bioanalytical service providers in North America," David Patteson, president and CEO of Advion BioSciences, said in a statement.

Advion noted that it received assistance from the Indiana Economic Development Corporation and BioCrossroads — Indiana's initiative for investment, development, and advancement of the life sciences industry — in expanding its operations in the state.

Among Advion BioServices' capabilities are LC/MS/MS services for the determination of small molecule drugs, biomarker discovery, immunoassay services, ADME screening, cytochrome P450 inhibition and induction study support, and metabolism profiling, among others.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more